Stocksigma LogoStocksigma Logo

Mahamaya Lifesciences Submits Monitoring Agency Report for September 2026

Mahamaya Lifesciences submitted its Monitoring Agency Report issued by Infomerics Valuation and Rating for the period ended 30th Sep'26, showing nil

Mahamaya Lifesciences Submits Monitoring Agency Report for September 2026

Mahamaya Lifesciences Ltd 路 Others (Uncategorized) 路 13 Nov 2026, 11:10 pm

Mahamaya Lifesciences Submits Monitoring Agency Report for September 2026 Mahamaya Lifesciences submitted its Monitoring Agency Report issued by Infomerics Valuation and Rating for the period ended 30th Sep'26, showing nil deviation in IPO proceeds utilization. Out of Rs. 61.96 crore net proceeds raised, the company utilized Rs. 32.72 crore cumulatively through Q2FY27 (including Rs. 1.03 crore in Q1FY27 and Rs. 2.52 crore in Q2FY27), leaving Rs. 29.24 crore unutilized in fixed deposits and monitoring accounts. The Board has rescheduled the deployment timeline for unutilized capex proceeds up to 31st Mar'28 due to phased plant execution.

Original exchange filing (PDF)

More announcements from Mahamaya Lifesciences Ltd

All Mahamaya Lifesciences Ltd announcements